Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIBF 1120 plus pemetrexed versus placebo plus pemetrexed in previously treated advanced non-small cell lung cancer
NL-OMON36930Phase 3Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing BIBF 1120 + pemetrexed with Placebo + pemetrexed (2 arms). Primary endpoint: Progression-free survival. Started Sep 2009; status: active, not recruiting.
02
Drugs
nintedanib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON36930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36930.